State Street Corp. Updates Karyopharm Therapeutics Stake
Ticker: KPTI · Form: SC 13G/A · Filed: Jan 22, 2024 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | SC 13G/A |
| Filed Date | Jan 22, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**State Street still owns Karyopharm shares, signaling continued institutional interest.**
AI Summary
State Street Corporation, a major financial institution, filed an amended Schedule 13G/A on January 22, 2024, indicating its ownership of Karyopharm Therapeutics Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, confirming their continued passive investment in the pharmaceutical company. For investors, this signals that a large institutional player maintains a position in Karyopharm, which can be seen as a vote of confidence, though the specific percentage of ownership is not detailed in the provided text.
Why It Matters
This filing shows that a significant institutional investor, State Street Corporation, continues to hold shares in Karyopharm Therapeutics, which can influence market perception and investor confidence.
Risk Assessment
Risk Level: low — This is a routine update from a large institutional investor and does not indicate any immediate risk or significant change in company fundamentals.
Analyst Insight
Investors should note that a major institution like State Street Corporation continues to hold Karyopharm Therapeutics stock, suggesting a baseline level of institutional confidence. However, this filing does not provide details on the percentage of ownership or any change in their stake, so further investigation into their specific holdings might be warranted for a complete picture.
Key Numbers
- 48576U106 — CUSIP Number (identifies Karyopharm Therapeutics Inc. common stock)
- 04-2456637 — IRS Identification No. (identifies State Street Corporation)
- 20240122 — Filed As Of Date (the date the SC 13G/A was filed)
Key Players & Entities
- State Street Corporation (company) — the reporting person filing the SC 13G/A
- Karyopharm Therapeutics Inc. (company) — the subject company whose securities are being reported
- 0000093751-24-000068 (dollar_amount) — accession number for the filing
- December 31, 2023 (date) — date of event which requires filing of this statement
Forward-Looking Statements
- State Street Corporation will maintain a passive investment in Karyopharm Therapeutics Inc. for the foreseeable future. (State Street Corporation) — medium confidence, target: 2025-01-22
FAQ
Who filed this SC 13G/A amendment?
State Street Corporation filed this SC 13G/A amendment, as indicated by 'NAME OF REPORTING PERSON: STATE STREET CORPORATION' and 'FILED BY: COMPANY CONFORMED NAME: STATE STREET CORP' in the filing.
What company's securities are the subject of this filing?
The securities of Karyopharm Therapeutics Inc. are the subject of this filing, as stated under 'SUBJECT COMPANY: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc.' and 'KARYOPHARM THERAPEUTICS INC (NAME OF ISSUER)'.
What type of security is being reported in this filing?
The filing reports on 'COMMON STOCK' of Karyopharm Therapeutics Inc., as specified under 'TITLE OF CLASS OF SECURITIES'.
When was the event that triggered this filing?
The event that triggered this filing occurred on '12/31/2023', as stated under 'DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT'.
What rule under the Securities Exchange Act of 1934 is this schedule filed under?
This schedule is filed under 'RULE 13D-1 (B)', as indicated by the checked box in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 22, 2024 regarding Karyopharm Therapeutics Inc. (KPTI).